Eikon Therapeutics
Clinical trials sponsored by Eikon Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo therapy targets tough lung cancer Results expected Dec 2026 (estimated)
- New PARP1 inhibitor IMP1734 enters human trials for advanced cancers Results expected Jun 2027 (estimated)